265 related articles for article (PubMed ID: 31695695)
1. Anti-p200 Pemphigoid: A Systematic Review.
Kridin K; Ahmed AR
Front Immunol; 2019; 10():2466. PubMed ID: 31695695
[TBL] [Abstract][Full Text] [Related]
2. Laboratory Diagnosis and Clinical Profile of Anti-p200 Pemphigoid.
Meijer JM; Diercks GF; Schmidt E; Pas HH; Jonkman MF
JAMA Dermatol; 2016 Aug; 152(8):897-904. PubMed ID: 27167149
[TBL] [Abstract][Full Text] [Related]
3. Anti-p200 pemphigoid.
Goletz S; Hashimoto T; Zillikens D; Schmidt E
J Am Acad Dermatol; 2014 Jul; 71(1):185-91. PubMed ID: 24767733
[TBL] [Abstract][Full Text] [Related]
4. Coexistence of Anti-p200 Pemphigoid and Psoriasis: A Systematic Review.
Xie YH; Wang SH; Li SZ; Zuo YG
Front Immunol; 2022; 13():839094. PubMed ID: 35317170
[TBL] [Abstract][Full Text] [Related]
5. From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid.
Dainichi T; Koga H; Tsuji T; Ishii N; Ohyama B; Ueda A; Natsuaki Y; Karashima T; Nakama T; Yasumoto S; Zillikens D; Hashimoto T
J Dermatol; 2010 Mar; 37(3):231-8. PubMed ID: 20507386
[TBL] [Abstract][Full Text] [Related]
6. [Anti-p200 pemphigoid: Remission under mycophenolate mofetil (Cellcept®)].
Raffin D; Delaplace M; Roussel A; Estève E
Ann Dermatol Venereol; 2013 Dec; 140(12):784-7. PubMed ID: 24315224
[TBL] [Abstract][Full Text] [Related]
7. [Anti-p200 pemphigoid: a spectacular response to dapsone].
Munsch C; Prey S; Joly P; Meyer N; Lamant L; Livideanu C; Viraben R; Paul C
Ann Dermatol Venereol; 2011 Nov; 138(11):739-42. PubMed ID: 22078034
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunological features and outcome of anti-p200 pemphigoid.
Commin MH; Schmidt E; Duvert-Lehembre S; Lasek A; Morice C; Estival JL; Debarbieux S; Rigal E; Pauwels C; De Quatrebarbes J; Roussel A; Goujon E; Stoebner PE; Jouen F; Joly P
Br J Dermatol; 2016 Oct; 175(4):776-81. PubMed ID: 27037896
[TBL] [Abstract][Full Text] [Related]
9. [Anti-p200 pemphigoid: clinical, diagnostic and therapeutic aspects].
Drerup KA; Wehkamp U
Hautarzt; 2020 Feb; 71(2):130-133. PubMed ID: 31501972
[TBL] [Abstract][Full Text] [Related]
10. Subepidermal blistering disease with autoantibodies to both the p200 autoantigen and the alpha3 chain of laminin 5.
Shimanovich I; Petersen EE; Weyers W; Sitaru C; Zillikens D
J Am Acad Dermatol; 2005 May; 52(5 Suppl 1):S90-2. PubMed ID: 15858518
[TBL] [Abstract][Full Text] [Related]
11. Anti-laminin gamma-1 pemphigoid.
Dainichi T; Kurono S; Ohyama B; Ishii N; Sanzen N; Hayashi M; Shimono C; Taniguchi Y; Koga H; Karashima T; Yasumoto S; Zillikens D; Sekiguchi K; Hashimoto T
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2800-5. PubMed ID: 19196964
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitor-associated anti-laminin-γ1 (p200) pemphigoid in a patient with psoriasis vulgaris.
Minakawa S; Matsuzaki Y; Hashimoto T; Ishii N; Nishie W; Kayaba H; Sawamura D
J Dermatol; 2020 Jan; 47(1):e25-e26. PubMed ID: 31646656
[No Abstract] [Full Text] [Related]
13. Case of subepidermal autoimmune bullous disease with psoriasis vulgaris reacting to both BP180 C-terminal domain and laminin gamma-1.
Ishida S; Takahashi K; Kanaoka M; Okawa T; Tateishi C; Yasukochi A; Ishii N; Li X; Hashimoto T; Aihara M
J Dermatol; 2015 Apr; 42(4):391-3. PubMed ID: 25683229
[TBL] [Abstract][Full Text] [Related]
14. Potential contribution of anti-p200 autoantibodies to mucosal lesions in anti-p200 pemphigoid.
Gao Y; Qian H; Hashimoto T; Li X
Front Immunol; 2023; 14():1118846. PubMed ID: 36761755
[TBL] [Abstract][Full Text] [Related]
15. Pemphigoid with antibodies to laminin γ1, BP180 and BP230, associated with psoriasis vulgaris: successful disease control with cyclosporin.
Imanishi A; Tateishi C; Imanishi H; Sowa-Osako J; Koga H; Tsuruta D; Hashimoto T
J Dermatol; 2015 Apr; 42(4):394-7. PubMed ID: 25708520
[TBL] [Abstract][Full Text] [Related]
16. IgA anti-p200 pemphigoid.
Wozniak K; Hashimoto T; Fukuda S; Ohyama B; Ishii N; Koga H; Dainichi T; Kowalewski C
Arch Dermatol; 2011 Nov; 147(11):1306-10. PubMed ID: 22106117
[TBL] [Abstract][Full Text] [Related]
17. Pathogenicity of autoantibodies in anti-p200 pemphigoid.
Vafia K; Groth S; Beckmann T; Hirose M; Dworschak J; Recke A; Ludwig RJ; Hashimoto T; Zillikens D; Schmidt E
PLoS One; 2012; 7(7):e41769. PubMed ID: 22911854
[TBL] [Abstract][Full Text] [Related]
18. Epidermolysis bullosa acquisita and anti-p200 pemphigoid as major subepidermal autoimmune bullous diseases diagnosed by floor binding on indirect immunofluorescence microscopy using human salt-split skin.
Goyal N; Rao R; Shenoi SD; Pai S; Kumar P; Bhogal BS; Schmidt E; Zillikens D
Indian J Dermatol Venereol Leprol; 2017; 83(5):550-555. PubMed ID: 28749386
[TBL] [Abstract][Full Text] [Related]
19. Two cases of subepidermal blistering disease with anti-p200 or 180-kD bullous pemphigoid antigen associated with psoriasis.
Yasuda H; Tomita Y; Shibaki A; Hashimoto T
Dermatology; 2004; 209(2):149-55. PubMed ID: 15316172
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of a Simple Immunohistochemical Staining Technique to Differentiate Anti-p200 Pemphigoid From Other Autoimmune Blistering Diseases: A Report of 2 Cases.
García-Díez I; Martínez-Escala ME; Ishii N; Hashimoto T; Mascaró Galy JM; Pujol RM; Herrero-González JE
Actas Dermosifiliogr; 2017; 108(1):e1-e5. PubMed ID: 27095685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
